Abstract:
The present invention provides novel sulfonylurea compounds of formula (I) and pharmaceutically acceptable derivatives and polymorph and amorphous forms thereof. The compounds in their various forms are effective platelet ADP receptor inhibitors and may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of cardiovascular diseases, particularly those diseases related to thrombosis. The invention also provides a method for preparing such compounds and forms and for preventing or treating thrombosis and thrombosis related conditions in a mammal comprising the step of administering a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or forms thereof.
Abstract:
LA PRÉSENTE INVENTION CONCERNE DES COMPOSÉS UTILISABLES EN TANT QU'INHIBITEURS DU RÉCEPTEUR PLAQUETTAIRE DE L'ADP DANS LE BUT DE TRAITER UNE THROMBOSE ET DE RÉDUIRE L'ÉVENTUALITÉ ET/OU LA SÉVÉRITÉ D'UN ÉVÉNEMENT ISCHÉMIQUE SECONDAIRE CHEZ UN PATIENT.
Abstract:
The invention provides methods and compositions for rapid and reversible inhibition of platelet aggregation in human subjects in need thereof by administering compounds of the formula: alone or in combination with a second agent which can be aspirin or a thrombolytic agent.